Literature DB >> 9381528

Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts.

K Seino1, N Kayagaki, N Tsukada, K Fukao, H Yagita, K Okumura.   

Abstract

BACKGROUND: CD95 and its ligand (CD95L) have been implicated in the regulation of immune responses. Recently, it was reported that CD95L expression prevented rejection of allogeneic grafts transplanted under the kidney capsule. In contrast, we reported that enforced CD95L expression in subcutaneously grafted cells induced acute rejection even in the syngeneic or immunodeficient hosts. In this study, we investigated whether the CD95L-expressing cells could be protected from rejection when transplanted under the kidney capsule.
METHODS: CD95-negative cells (baby hamster kidney and L5178Y lymphoma cells) were transfected with CD95L cDNA to express functional CD95L. The cells were transplanted into skin or renal subcapsular space of immunocompetent or T cell-deficient nu/nu mice.
RESULTS: The parental cells grew well in nu/nu or syngeneic mice but were rejected in allogeneic or xenogeneic immunocompetent mice. The CD95L transfectants were rejected when transplanted subcutaneously in all types of mice studied. However, when transplanted under the kidney capsule, they survived in nu/nu or syngeneic mice but were rejected in allogeneic or xenogeneic immunocompetent mice.
CONCLUSIONS: These results imply that CD95L expression may not be sufficient to protect the grafts from rejection, and the survival of CD95L-bearing grafts is substantially influenced by the site of transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9381528     DOI: 10.1097/00007890-199710150-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

2.  Fas ligand enhances malignant behavior of tumor cells through interaction with Met, hepatocyte growth factor receptor, in lipid rafts.

Authors:  Huan-Ching Lin; Po-Yin Lai; Yu-ping Lin; Jyun-Yuan Huang; Bei-Chang Yang
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

3.  Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice.

Authors:  C C Chio; Y S Wang; Y L Chen; S J Lin; B C Yang
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

4.  Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.

Authors:  A Houston; M W Bennett; G C O'Sullivan; F Shanahan; J O'Connell
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

5.  Granulocytes mediates the Fas-L-associated apoptosis during lung metastasis of melanoma that determines the metastatic behaviour.

Authors:  Y-L Chen; J-Y Wang; S-H Chen; B-C Yang
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.